These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38372729)

  • 1. Intravenous immunoglobulin in the treatment of sporadic inclusion body myositis: time for new evidence?
    Fontanelli L; Vadi G; Schirinzi E; Di Rauso G; Bellini G; Ricci G; Siciliano G
    Clin Exp Rheumatol; 2024 Feb; 42(2):462-463. PubMed ID: 38372729
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-lasting effectiveness of intravenous immunoglobulin in a patient with inclusion-body myositis.
    Mukunda BN; Dileep Kumar P; Smith HR
    Ann Intern Med; 2001 Jun; 134(12):1156. PubMed ID: 11412071
    [No Abstract]   [Full Text] [Related]  

  • 3. Inclusion body myositis: therapeutic approaches. A case report.
    Kierdaszuk B; Kamińska A
    Neurol Neurochir Pol; 2011; 45(1):68-73. PubMed ID: 21384296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients.
    Dobloug C; Walle-Hansen R; Gran JT; Molberg Ø
    Clin Exp Rheumatol; 2012; 30(6):838-42. PubMed ID: 22935197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin for dysphagia of inclusion body myositis.
    Cherin P; Pelletier S; Teixeira A; Laforet P; Simon A; Herson S; Eymard B
    Neurology; 2002 Jan; 58(2):326. PubMed ID: 11805271
    [No Abstract]   [Full Text] [Related]  

  • 6. Inclusion body myositis: treatment with intravenous immunoglobulin.
    Amato AA; Barohn RJ; Jackson CE; Pappert EJ; Sahenk Z; Kissel JT
    Neurology; 1994 Aug; 44(8):1516-8. PubMed ID: 8058161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term observational study of sporadic inclusion body myositis.
    Benveniste O; Guiguet M; Freebody J; Dubourg O; Squier W; Maisonobe T; Stojkovic T; Leite MI; Allenbach Y; Herson S; Brady S; Eymard B; Hilton-Jones D
    Brain; 2011 Nov; 134(Pt 11):3176-84. PubMed ID: 21994327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis).
    Pongratz D
    J Neurol; 2006 Sep; 253 Suppl 5():V64-5. PubMed ID: 16998756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease.
    Dalakas MC
    J Clin Immunol; 1995 Nov; 15(6 Suppl):70S-75S. PubMed ID: 8613495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic dilemma of inclusion body myositis.
    Barohn RJ
    Neurology; 1997 Mar; 48(3):567-8. PubMed ID: 9065526
    [No Abstract]   [Full Text] [Related]  

  • 11. [A rare case of inclusion body myositis associated with anti-PM/Scl-75 antibodies].
    Yamamoto M; Tsuzaki K; Itani K; Tachibana N; Inoue M; Hamano T
    Rinsho Shinkeigaku; 2020 Apr; 60(4):264-267. PubMed ID: 32238743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.
    Foreman C; Russo P; Davies N; Hissaria P; Proudman S; Hughes T; Limaye V
    Intern Med J; 2017 Jan; 47(1):112-115. PubMed ID: 28076913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose immunoglobulin therapy in a case of inclusion body myositis: clinical and immunologic aspects.
    Salvarani C; Boiardi L; Maldini MC; Mancini R; Rinaldi M; Macchioni P; Portioli I
    J Rheumatol; 1993 Aug; 20(8):1455-6. PubMed ID: 8230050
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?
    Recher M; Sahrbacher U; Bremer J; Arndt B; Steiner U; Fontana A
    Rheumatol Int; 2012 Feb; 32(2):469-72. PubMed ID: 20044785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sporadic inclusion body myositis misdiagnosed as idiopathic granulomatous myositis.
    Lavian M; Goyal N; Mozaffar T
    Neuromuscul Disord; 2016 Nov; 26(11):741-743. PubMed ID: 27692540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent anti-PM-Scl antibody-associated systemic sclerosis and inclusion body myositis - report of two cases and review of the literature.
    Chatterjee S; Prayson RA
    Semin Arthritis Rheum; 2020 Jun; 50(3):498-502. PubMed ID: 31806155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common variable immunodeficiency (CVID) and inclusion body myositis (IBM).
    Gause A; Inderrieden DC; Laas R; Arlt AC; Gross WL
    Immunobiology; 2000 Aug; 202(2):199-203. PubMed ID: 10993295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic approaches in patients with inflammatory myopathies.
    Dalakas MC
    Semin Neurol; 2003 Jun; 23(2):199-206. PubMed ID: 12894385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.
    Quick A; Tandan R
    Curr Rheumatol Rep; 2011 Jun; 13(3):192-8. PubMed ID: 21503696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of inflammatory myopathy with intravenous gamma globulin.
    Sussman GL; Pruzanski W
    Curr Opin Rheumatol; 1995 Nov; 7(6):510-5. PubMed ID: 8579971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.